دورية أكاديمية
The clinicopathological significance of monocarboxylate transporters in testicular germ cell tumors.
| العنوان: | The clinicopathological significance of monocarboxylate transporters in testicular germ cell tumors. |
|---|---|
| المؤلفون: | Silva ECA; Pathology Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil., Cárcano FM; Medical Oncology Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.; Barretos School of Health Sciences Dr. Paulo Prata - FACISB, Barretos, São Paulo, Brazil., Bonatelli M; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil., Zaia MG; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil., Morais-Santos F; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal., Baltazar F; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal., Lopes LF; Barretos School of Health Sciences Dr. Paulo Prata - FACISB, Barretos, São Paulo, Brazil.; Barretos Children's Cancer Hospital, Barretos, São Paulo, Brazil., Scapulatempo-Neto C; Pathology Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil., Pinheiro C; Barretos School of Health Sciences Dr. Paulo Prata - FACISB, Barretos, São Paulo, Brazil.; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil. |
| المصدر: | Oncotarget [Oncotarget] 2018 Apr 17; Vol. 9 (29), pp. 20386-20398. Date of Electronic Publication: 2018 Apr 17 (Print Publication: 2018). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Albany, N.Y. : Impact Journals |
| مستخلص: | Background: Metabolic reprogramming is one of the hallmarks of cancer. The hyperglycolytic phenotype is often associated with the overexpression of metabolism-associated proteins, such as monocarboxylate transporters (MCTs). MCTs are little explored in germ cell tumors (GCTs), thus, the opportunity to understand the relevance of these metabolic markers and their chaperone CD147 in this type of tumor arises. The main aim of this study was to evaluate the expression of MCT1, MCT2, MCT4 and CD147 in testicular GCT samples and the clinicopathological significance of these metabolism related proteins. Results: MCT1, MCT4 and CD147 were associated with higher stages, higher M and N stages and histological type, while MCT4 was also associated with higher risk stratification, presence of vascular invasion, and lower overall and event free survival. MCT4 silencing in JEG-3 had no significant effect in cell viability, proliferation and death, as well as extracellular levels of glucose and lactate. However, MCT4-silenced cells showed an increase in migration and invasion. Conclusion: The proteins herein studied, with the exception of MCT2, were associated with characteristics of worse prognosis, lower global and event free survival of patients with GCTs. Also, in vitro MCT4 silencing stimulated cell migration and invasion. Materials and Methods: Immunohistochemical expression was evaluated on samples from 149 adult patients with testicular GCT, arranged in Tissue Microarrays (TMAs), and associated with the clinicopathological data. Also, MCT4 silencing studies using siRNA were performed in JEG-3 cells. Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest. |
| References: | Science. 1956 Feb 24;123(3191):309-14. (PMID: 13298683) Neurosurgery. 2004 Dec;55(6):1410-9; discussion 1419. (PMID: 15574223) World J Gastroenterol. 2014 Sep 7;20(33):11780-7. (PMID: 25206282) Curr Opin Oncol. 2013 May;25(3):266-72. (PMID: 23549473) J Biol Chem. 2005 Jul 22;280(29):27213-21. (PMID: 15917240) Neuro Oncol. 2013 Feb;15(2):172-88. (PMID: 23258846) EMBO J. 2000 Aug 1;19(15):3896-904. (PMID: 10921872) Cell Cycle. 2016 Jun 2;15(11):1462-70. (PMID: 27105345) PLoS One. 2013;8(2):e54072. (PMID: 23457446) Urology. 2014 Jul;84(1):245.e9-15. (PMID: 24857275) Liver Int. 2014 Jul;34(6):942-52. (PMID: 24433439) Cell Cycle. 2016 Jul 17;15(14 ):1865-73. (PMID: 27232157) J Pharm Sci. 2003 Aug;92(8):1531-44. (PMID: 12884241) J Transl Med. 2014 May 09;12:118. (PMID: 24885736) J Clin Oncol. 2014 Oct 1;32(28):3085-92. (PMID: 25024068) J Biol Chem. 2011 Aug 5;286(31):27781-91. (PMID: 21680735) Appl Immunohistochem Mol Morphol. 2013 Oct;21(5):401-7. (PMID: 23343953) Nat Rev Cancer. 2013 Sep;13(9):611-23. (PMID: 23969692) Cell Oncol (Dordr). 2016 Jun;39(3):253-63. (PMID: 26920031) Urology. 1999 Nov;54(5):900-4. (PMID: 10565755) Eur J Cancer. 2009 Sep;45(13):2418-24. (PMID: 19628385) Cancer Res. 2015 Jan 1;75(1):171-80. (PMID: 25403912) Virchows Arch. 2008 Feb;452(2):139-46. (PMID: 18188595) J Biomed Biotechnol. 2010;2010:427694. (PMID: 20454640) Histopathology. 2010 Jun;56(7):860-7. (PMID: 20636790) PLoS One. 2014 Jan 30;9(1):e87904. (PMID: 24498219) Dis Markers. 2009;26(3):97-103. (PMID: 19597291) BMC Cancer. 2011 Jul 25;11:312. (PMID: 21787388) J Bioenerg Biomembr. 2012 Feb;44(1):171-8. (PMID: 22281667) Hum Pathol. 2015 Jan;46(1):104-12. (PMID: 25456395) Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) Nat Rev Drug Discov. 2011 Aug 31;10(9):671-84. (PMID: 21878982) Anticancer Res. 1997 Jul-Aug;17(4A):2747-50. (PMID: 9252709) BMC Cancer. 2014 Oct 08;14:751. (PMID: 25296855) Cancer Sci. 2011 May;102(5):1007-13. (PMID: 21306479) J Cancer Res Clin Oncol. 2015 Jul;141(7):1151-62. (PMID: 25446815) Int J Gynecol Pathol. 2008 Oct;27(4):568-74. (PMID: 18753962) Biochem Biophys Res Commun. 2014 Aug 15;451(1):54-61. (PMID: 25058459) IUBMB Life. 2012 Jan;64(1):1-9. (PMID: 22131303) Cell Metab. 2016 Jan 12;23 (1):27-47. (PMID: 26771115) J Biol Chem. 1998 Oct 30;273(44):28959-65. (PMID: 9786900) Oncotarget. 2016 May 31;7(22):32695-706. (PMID: 27127175) Lung Cancer. 2012 Jun;76(3):316-23. (PMID: 22153830) Oncotarget. 2015 Mar 30;6(9):6708-21. (PMID: 25894929) Lancet. 2016 Apr 23;387(10029):1762-74. (PMID: 26651223) Ann Oncol. 2012 Jan;23 (1):59-64. (PMID: 21460378) J Bioenerg Biomembr. 2012 Feb;44(1):127-39. (PMID: 22407107) Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):318-21. (PMID: 23165333) Nat Rev Urol. 2016 Jul;13(7):409-19. (PMID: 27296647) Pediatr Blood Cancer. 2004 Feb;42(2):169-75. (PMID: 14752882) BMC Cancer. 2015 Nov 02;15:835. (PMID: 26525902) Oncogene. 2014 Jul 31;33(31):4060-8. (PMID: 24166504) Pancreas. 2016 Aug;45(7):1036-47. (PMID: 26765963) Cancer Treat Rev. 2003 Dec;29(6):541-9. (PMID: 14585264) BMC Cancer. 2016 Jul 26;16:535. (PMID: 27460659) Oncotarget. 2015 Dec 29;6(42):44403-21. (PMID: 26587828) J Clin Invest. 2008 Dec;118(12):3930-42. (PMID: 19033663) Diagn Cytopathol. 2012 Jun;40(6):478-83. (PMID: 22619123) Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998) Gut. 2009 Oct;58(10):1391-8. (PMID: 19505879) J Clin Oncol. 2008 Dec 20;26(36):5930-5. (PMID: 19018083) Am J Physiol Cell Physiol. 2009 Mar;296(3):C414-21. (PMID: 19073896) Histol Histopathol. 2014 Dec;29(12 ):1511-24. (PMID: 24921258) Biomed Res Int. 2015 ;2015 :242437. (PMID: 26779534) Br J Cancer. 2015 Jul 28;113(3):411-3. (PMID: 26171934) Oncotarget. 2015 Aug 7;6(22):19177-89. (PMID: 26203664) |
| فهرسة مساهمة: | Keywords: Warburg effect; immunohistochemistry; monocarboxylate transporter; testicular germ cell tumors; testicular neoplasms |
| تواريخ الأحداث: | Date Created: 20180515 Latest Revision: 20220318 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC5945514 |
| DOI: | 10.18632/oncotarget.24910 |
| PMID: | 29755659 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1949-2553 |
|---|---|
| DOI: | 10.18632/oncotarget.24910 |